Treatment of Uncomplicated Urethral Gonorrhea in Adult Males
Treat with ceftriaxone 500 mg intramuscularly as a single dose, and add doxycycline 100 mg orally twice daily for 7 days if chlamydial coinfection has not been excluded.
Primary Treatment Regimen
The most recent evidence from 2020-2022 establishes ceftriaxone monotherapy as first-line treatment, representing an evolution from earlier dual therapy recommendations 1, 2. The dose was increased from 250 mg to 500 mg based on updated pharmacokinetic/pharmacodynamic data and antimicrobial stewardship principles 1.
For patients weighing <150 kg (331 lbs):
For chlamydial coinfection management:
- Add doxycycline 100 mg orally twice daily for 7 days if C. trachomatis has not been excluded 2, 3
- This addresses the high coinfection rate (20-40% in many populations) 4
Rationale for Current Recommendations
The shift away from routine azithromycin dual therapy reflects critical surveillance data showing azithromycin resistance rising to nearly 5% by 2018, while ceftriaxone minimal inhibitory concentrations (MICs) have remained stable with <0.1% showing alert values 1. This change prioritizes antimicrobial stewardship while maintaining treatment efficacy, as ceftriaxone alone demonstrates 99.1% cure rates for urogenital infections 5.
The addition of doxycycline specifically targets chlamydia rather than gonorrhea, acknowledging that most patients receive same-day empiric treatment before test results return 6. Doxycycline is now preferred over azithromycin for chlamydial coverage to preserve azithromycin effectiveness against gonorrhea 1.
Alternative Regimens
If ceftriaxone is unavailable:
- Cefixime 400 mg orally once PLUS azithromycin 1 g orally once (or doxycycline 100 mg twice daily for 7 days)
- Mandatory test-of-cure at 1 week 5
- Note: Cefixime is no longer first-line due to rising MICs and limited pharyngeal efficacy 5
If severe cephalosporin allergy:
- Azithromycin 2 g orally once
- Mandatory test-of-cure at 1 week 5
- Limited alternative options exist; no recommended alternatives for pharyngeal infection 1
Emerging option (investigational):
- Gepotidacin demonstrated non-inferiority to ceftriaxone plus azithromycin in 2025 phase 3 trial, offering potential future oral alternative 7
Critical Management Points
Test-of-cure is NOT routinely needed for patients treated with recommended ceftriaxone regimen who are asymptomatic after treatment 8. However, test-of-cure IS mandatory for:
- Alternative regimens (cefixime or azithromycin monotherapy) at 1 week 5
- Persistent symptoms after treatment 5
- Suspected treatment failure 5
Reinfection screening is essential:
- Retest ALL treated patients at 3-6 months regardless of partner treatment status 8, 3
- High reinfection rates (not treatment failures) drive this recommendation 8
Partner management:
- Treat all partners from preceding 60 days 5
- Patient should abstain from intercourse until therapy completed and partners treated 8
Treatment Failure Protocol
If symptoms persist after recommended therapy:
- Culture specimens and perform antimicrobial susceptibility testing 5
- Consult infectious disease specialist or CDC (404-639-8659) 5
- Report to local/state health department within 24 hours 5
- Ensure partner evaluation with culture 5
Common Pitfalls to Avoid
- Do not use fluoroquinolones - widespread resistance makes them obsolete for gonorrhea treatment 9, 1
- Do not use cefixime as first-line - rising MICs and poor pharyngeal coverage 5
- Do not routinely add azithromycin to ceftriaxone unless specifically treating presumptive chlamydia - this represents outdated 2015 guidance 1, 2
- Do not skip doxycycline if chlamydia testing unavailable and patient may not return for results 4
- Do not forget concurrent STI testing - screen for syphilis, HIV, and other infections 10
The evidence strongly supports ceftriaxone 500 mg IM as the most effective single-agent therapy for urethral gonorrhea, with targeted chlamydial coverage added based on testing availability and patient follow-up likelihood.